"Delivery of this report will take 1-3 days after purchase."
The Global Respiratory Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies
Global Respiratory Partnering 2010 to 2017 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Trends in Respiratory partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Respiratory partnering agreement structure
Respiratory partnering contract documents
Top Respiratory deals by value
Most active Respiratory dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Respiratory dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Respiratory deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Respiratory deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2010. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.
Global Respiratory Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.
Global Respiratory Partnering 2010 to 2017 includes:
Trends in Respiratory dealmaking in the biopharma industry since 2010
Analysis of Respiratory deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Respiratory deal contract documents
Comprehensive access to over 3500 Respiratory deal records
The leading Respiratory deals by value since 2010
Most active Respiratory dealmakers since 2010
The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.
In Global Respiratory Partnering 2010 to 2017, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Respiratory Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 respiratory deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Respiratory Partnering 2010 to 2017 provides the reader with the following key benefits:
In-depth understanding of Respiratory deal trends since 2010
Access Respiratory deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Respiratory partner companies
Comprehensive access to over 750 links to actual Respiratory deals entered into by the world's biopharma companies
Indepth review of Respiratory deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Respiratory opportunities
Uncover companies actively partnering Respiratory opportunities